Skip to main content
Top
Published in: Supportive Care in Cancer 9/2012

01-09-2012 | Original Article

Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists

Authors: C. C. Henson, S. E. Davidson, A. Lalji, R. P. Symonds, R. Swindell, H. J. N. Andreyev

Published in: Supportive Care in Cancer | Issue 9/2012

Login to get access

Abstract

Purpose

Seventeen thousand patients receive treatment with radical pelvic radiotherapy annually in the UK. Up to 50% develop significant gastrointestinal symptoms. The National Cancer Survivorship Initiative has identified access to specialist medical care for those with complications after cancer as one of their four key needs. We aimed to determine the current practice of British gastroenterologists with regards to chronic gastrointestinal symptoms after pelvic radiotherapy.

Methods

A questionnaire was developed and sent up to a maximum of five times to all UK consultant gastroenterologists.

Results

Eight hundred sixty-six gastroenterologists were approached and 165 (20%) responded. Sixty-one percent saw one to four patients annually with bowel symptoms after radiotherapy. Eighteen percent rate the current treatments as effective “often” or “most of the time”. Forty-seven percent of gastroenterologists consider themselves “confident with basic cases”, with 11% “confident in all cases”. Fifty-nine percent thinks a gastroenterologist with a specialist interest should manage these patients. Although only 29% thinks a specific service is required for these patients, 34% rates the current service as inadequate. The ideal service was considered to be gastroenterology-led, multidisciplinary and regional. Low referral rates, poor evidence-base and poor funding are cited as reasons for the current patchy services.

Conclusions

The low response rate contrasts with that from a parallel survey of clinical oncologists. This may reflect the opinion that radiation-induced bowel toxicity is not a significant issue, which may be because only a small proportion of patients are referred to gastroenterologists. The development of new, evidence-based gastroenterology-led services is considered the optimal way to meet the needs of these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference West CML, Davidson SE (2009) Measurement tools for gastrointestinal symptoms in radiation oncology. Curr Opin Support Palliat Care 3(1):36–40PubMedCrossRef West CML, Davidson SE (2009) Measurement tools for gastrointestinal symptoms in radiation oncology. Curr Opin Support Palliat Care 3(1):36–40PubMedCrossRef
2.
go back to reference Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P (2010) Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a royal college of radiologists’ audit. Clin Oncol 22(7):590–601CrossRef Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P (2010) Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a royal college of radiologists’ audit. Clin Oncol 22(7):590–601CrossRef
3.
go back to reference Ryu H-S, Chun M, Chang K-H, Chang H-J, Lee J-P (2005) Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol 96(2):490–495PubMedCrossRef Ryu H-S, Chun M, Chang K-H, Chang H-J, Lee J-P (2005) Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol 96(2):490–495PubMedCrossRef
4.
go back to reference Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358(9284):781–786PubMedCrossRef Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358(9284):781–786PubMedCrossRef
5.
go back to reference Creutzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 355(9213):1404–1411PubMedCrossRef Creutzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 355(9213):1404–1411PubMedCrossRef
6.
go back to reference Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C (1997) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077):535–540PubMedCrossRef Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C (1997) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077):535–540PubMedCrossRef
7.
go back to reference Bergmark K, AVall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G (2002) Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 81(5):443–450PubMedCrossRef Bergmark K, AVall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G (2002) Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 81(5):443–450PubMedCrossRef
8.
go back to reference Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, Bydder S, Wright S (1999) Is there more than one late radiation proctitis syndrome? Radiother Oncol 51(1):43–53PubMedCrossRef Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, Bydder S, Wright S (1999) Is there more than one late radiation proctitis syndrome? Radiother Oncol 51(1):43–53PubMedCrossRef
9.
go back to reference DeCosse JJ, Rhodes RS, Wentz WB, Reagan JW, Dworken HJ, Holden WD (1969) The natural history and management of radiation induced injury of the gastrointestinal tract. Ann Surg 170(3):369–384PubMedCrossRef DeCosse JJ, Rhodes RS, Wentz WB, Reagan JW, Dworken HJ, Holden WD (1969) The natural history and management of radiation induced injury of the gastrointestinal tract. Ann Surg 170(3):369–384PubMedCrossRef
10.
go back to reference Schofield PF, Holden D, Carr ND (1983) Bowel disease after radiotherapy. J R Soc Med 76(6):463–466PubMed Schofield PF, Holden D, Carr ND (1983) Bowel disease after radiotherapy. J R Soc Med 76(6):463–466PubMed
11.
go back to reference Andreyev HJN, Wotherspoon A, Denham JW, Hauer-Jensen M (2010) Defining pelvic-radiation disease for the survivorship era. Lancet Oncol 11(4):310–312PubMedCrossRef Andreyev HJN, Wotherspoon A, Denham JW, Hauer-Jensen M (2010) Defining pelvic-radiation disease for the survivorship era. Lancet Oncol 11(4):310–312PubMedCrossRef
12.
go back to reference Davidson SE, Trotti A, Ataman ÖU, Seong J, Lau FN, da Motta NW, Jeremic B (2007) Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 69(4):1218–1221PubMedCrossRef Davidson SE, Trotti A, Ataman ÖU, Seong J, Lau FN, da Motta NW, Jeremic B (2007) Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 69(4):1218–1221PubMedCrossRef
13.
go back to reference Andreyev J (2007) Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 8(11):1007–1017PubMedCrossRef Andreyev J (2007) Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 8(11):1007–1017PubMedCrossRef
14.
go back to reference Andreyev HJN, Vlavianos P, Blake P, Dearnaley D, Norman AR, Tait D (2005) Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist? Int J Radiat Oncol Biol Phys 62(5):1464–1471PubMedCrossRef Andreyev HJN, Vlavianos P, Blake P, Dearnaley D, Norman AR, Tait D (2005) Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist? Int J Radiat Oncol Biol Phys 62(5):1464–1471PubMedCrossRef
15.
go back to reference Andreyev HJN, Amin Z, Blake P, Dearnaley D, Henry M, Tait D, Vlavianos P (2003) GI symptoms developing after pelvic radiotherapy require gastroenterological review but is this happening in the UK? Clin Oncol 15(2):S12 Andreyev HJN, Amin Z, Blake P, Dearnaley D, Henry M, Tait D, Vlavianos P (2003) GI symptoms developing after pelvic radiotherapy require gastroenterological review but is this happening in the UK? Clin Oncol 15(2):S12
16.
go back to reference Faithfull S (1995) ‘Just grin and bear it and hope that it will go away’: coping with urinary symptoms from pelvic radiotherapy. Eur J Cancer Care 4(4):158–165CrossRef Faithfull S (1995) ‘Just grin and bear it and hope that it will go away’: coping with urinary symptoms from pelvic radiotherapy. Eur J Cancer Care 4(4):158–165CrossRef
17.
go back to reference Putta S, Andreyev HJ (2005) Faecal incontinence: a late side-effect of pelvic radiotherapy. Clin Oncol 17(6):469–477CrossRef Putta S, Andreyev HJ (2005) Faecal incontinence: a late side-effect of pelvic radiotherapy. Clin Oncol 17(6):469–477CrossRef
18.
go back to reference Henson C, Andreyev HJN, Symonds RP, Peel D, Swindell R, Davidson SE (2011) Late onset bowel dysfunction post-pelvic radiotherapy: a national survey of current practice and opinions of clinical oncologists. Clin Oncol 23:552–557CrossRef Henson C, Andreyev HJN, Symonds RP, Peel D, Swindell R, Davidson SE (2011) Late onset bowel dysfunction post-pelvic radiotherapy: a national survey of current practice and opinions of clinical oncologists. Clin Oncol 23:552–557CrossRef
19.
go back to reference Ludgate SM, Merrick MV (1985) The pathogenesis of post-irradiation chronic diarrhoea: measurement of SeHCAT and B12 absorption for differential diagnosis determines treatment. Clin Radiol 36(3):275–278PubMedCrossRef Ludgate SM, Merrick MV (1985) The pathogenesis of post-irradiation chronic diarrhoea: measurement of SeHCAT and B12 absorption for differential diagnosis determines treatment. Clin Radiol 36(3):275–278PubMedCrossRef
20.
go back to reference Arlow FL, Dekovich AA, Priest RJ, Beher WT (1987) Bile acids in radiation-induced diarrhea. South Med J 80(10):1259–1261PubMedCrossRef Arlow FL, Dekovich AA, Priest RJ, Beher WT (1987) Bile acids in radiation-induced diarrhea. South Med J 80(10):1259–1261PubMedCrossRef
21.
go back to reference Danielsson A, Nyhlin H, Persson H, Stendahl U, Stenling R, Suhr O (1991) Chronic diarrhoea after radiotherapy for gynaecological cancer: occurrence and aetiology. Gut 32(10):1180–1187PubMedCrossRef Danielsson A, Nyhlin H, Persson H, Stendahl U, Stenling R, Suhr O (1991) Chronic diarrhoea after radiotherapy for gynaecological cancer: occurrence and aetiology. Gut 32(10):1180–1187PubMedCrossRef
22.
go back to reference Ford GA, Preece JD, Davies IH, Wilkinson SP (1992) Use of the SeHCAT test in the investigation of diarrhoea. Postgrad Med J 68(798):272–276PubMedCrossRef Ford GA, Preece JD, Davies IH, Wilkinson SP (1992) Use of the SeHCAT test in the investigation of diarrhoea. Postgrad Med J 68(798):272–276PubMedCrossRef
23.
go back to reference Beer WH, Fan A, Halsted CH (1985) Clinical and nutritional implications of radiation enteritis. Am J Clin Nutr 41(1):85–91PubMed Beer WH, Fan A, Halsted CH (1985) Clinical and nutritional implications of radiation enteritis. Am J Clin Nutr 41(1):85–91PubMed
24.
go back to reference Rougier P, Zimmermann P, Pignon JP, Kac J, Crespon B, Zrihen E, Charbit M, Gerbaulet A, Eschwege F (1992) Radiation proctitis: compared efficacy of two corticosteroids enemas. Med Chir Dig 21(2):91–93 Rougier P, Zimmermann P, Pignon JP, Kac J, Crespon B, Zrihen E, Charbit M, Gerbaulet A, Eschwege F (1992) Radiation proctitis: compared efficacy of two corticosteroids enemas. Med Chir Dig 21(2):91–93
25.
go back to reference Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R, Goenka MK, Gupta BD, Mehta SK (1991) Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 36(1):103–107PubMedCrossRef Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R, Goenka MK, Gupta BD, Mehta SK (1991) Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 36(1):103–107PubMedCrossRef
26.
go back to reference Cavcic J, Turcić J, Martinac P, Jelincić Z, Zupancić B, Panijan-Pezerović R, Unusić J (2000) Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med Journal 41:314–318 Cavcic J, Turcić J, Martinac P, Jelincić Z, Zupancić B, Panijan-Pezerović R, Unusić J (2000) Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med Journal 41:314–318
27.
go back to reference Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H (2009) Cancer prevelence in the United Kingdom: estimates for 2008. Br J Cancer 101(3):541–547PubMedCrossRef Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H (2009) Cancer prevelence in the United Kingdom: estimates for 2008. Br J Cancer 101(3):541–547PubMedCrossRef
28.
go back to reference De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777–787PubMedCrossRef De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777–787PubMedCrossRef
29.
go back to reference Henderson A, Ismail AK, Cunningham M, Aldridge S, Loverock L, Langley SE, Laing RW (2004) Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 16(2):95–104CrossRef Henderson A, Ismail AK, Cunningham M, Aldridge S, Loverock L, Langley SE, Laing RW (2004) Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 16(2):95–104CrossRef
30.
go back to reference Hackett C (2005) Pelvic radiotherapy and GI side effects: Hobson’s choice? Gastrointest Nurs 3:18–24 Hackett C (2005) Pelvic radiotherapy and GI side effects: Hobson’s choice? Gastrointest Nurs 3:18–24
31.
go back to reference Benton B, Norton C, Lindsay JO, Dolan S, Andreyev HJ (2011) Can nurses manage gastrointestinal symptoms arising from pelvic radiation disease? Clin Oncol 23:538–551CrossRef Benton B, Norton C, Lindsay JO, Dolan S, Andreyev HJ (2011) Can nurses manage gastrointestinal symptoms arising from pelvic radiation disease? Clin Oncol 23:538–551CrossRef
Metadata
Title
Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists
Authors
C. C. Henson
S. E. Davidson
A. Lalji
R. P. Symonds
R. Swindell
H. J. N. Andreyev
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1323-5

Other articles of this Issue 9/2012

Supportive Care in Cancer 9/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine